Vivimed Labs share news and announcements
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Last close ₹6.09down ₹0.12 (1.93%)BSE ₹6.11
Share price at the NSE close on 23 Oct 2026. Previous close ₹6.21.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹50 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day.
- 75
Vivimed Labs share news and announcements
653 announcements, routine notices left out, newest first. Page 2 of 14.
Sep 2025
Aug 2025
13 Aug · Board meeting
Jul 2025
15 Jul · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. The response of the Company is awaited.15 Jul · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Jun 2025
30 Jun · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
May 2025
Apr 2025
15 Apr · Updates
Mar 2025
Feb 2025
15 Feb · Results
Jan 2025
11 Jan · Board meeting
Dec 2024
Nov 2024
Oct 2024
Sep 2024
6 Sep · Board meeting
Aug 2024
Jul 2024
5 Jul · Board meeting
Jun 2024
May 2024
20 May · Management
20 May · Management
8 May · Board meeting
Not held on this date
4 May · Address Change
Apr 2024